– UK, Winsford – Advanced Medical Solutions Group plc (LON: AMS), the world-leading specialist in tissue-healing technologies, today announced the appointment of Liz Shanahan to its Board as an Independent Non-Executive Director with immediate effect.
“I am very pleased to welcome Liz to the Board of AMS, who brings with her significant experience in healthcare organisations, as well as specialist skills in communication and Executive coaching. She will be an extremely valuable addition to our Board,” said Board Chairman, Peter Allen.
About Liz Shanahan
Liz Shanahan is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. She is currently a Non-Executive Director of Inspiration Healthcare Group plc and Celadon Pharmaceuticals plc (previously Summerway Capital plc), both of which are AIM-listed. Most recently, she was a Non-Executive Director of UDG Healthcare plc, a company that was listed on the London Stock Exchange and a constituent of the FTSE 250 up until its £2.8 billion takeover in August 2021.
Until 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc., which in 2007 acquired the communications business Santé Communications, founded by Liz in 1995. Liz is a Trustee of CW+, the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London, and a member of the organization’s Innovations Advisory Board. Alongside her Board appointments, she is a business advisor and Executive coach.
Liz Shanahan said: “I have been watching AMS’s progress closely during my career and am very excited to be joining the Board of such a high-quality Company.”
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, hemostats, internal fixation devices, and internal sealants, which it markets under its brands LiquiBand, RESORBA, LiquiBandFix8, and Seal-G. AMS also supplies wound care dressings such as silver alginates, alginates, and foams through its ActivHeal brand as well as under a white label. Since 2019, the Group has made four acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for wound care and bio-diagnostics products and AFS Medical, a specialist distributor of minimally invasive surgical devices based in Austria.
AMS’s products, manufactured in the UK, Germany, France, Israel, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic, and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees.
For more information: https://www.admedsol.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.